Monitor the upcoming webcast for clinical data strength, but assess whether the results justify the legal risk. Watch for any escalation in the RevMed dispute, including a formal lawsuit filing or preliminary injunction motion, which could severely impact ERAS-0015's development timeline and valuation.
ERAS drugs
ERAS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $19.15entry
- T+1 · 7mo ago −48.30%α −47.82% · $9.90
- T+5 · 7mo ago −47.05%α −47.45% · $10.14
- T+20 · 6mo ago −39.95%α −44.90% · $11.50
- T+60 · 4mo ago +1.88%α −2.90% · $19.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Erasca disclosed preliminary Phase 1 data for its RAS-targeting drug ERAS-0015 while simultaneously revealing a patent and trade secret infringement claim from Revolution Medicines. The litigation threat over a key asset creates significant near-term uncertainty despite the positive clinical update.
Key Facts
- Erasca announced a webcast to discuss preliminary Phase 1 dose escalation data for ERAS-0015, a pan-RAS molecular glue for RAS-mutant solid tumors.
- Revolution Medicines (RevMed) alleged that ERAS-0015 infringes its U.S. Patent No. 12,409,225 under the doctrine of equivalents.
- RevMed also claimed Erasca is liable for misappropriation of trade secrets related to ERAS-0015 and accused the company of making deceptive comparative statements.
- RevMed demanded Erasca cease all development and commercialization activities for ERAS-0015 in the U.S. outside the Hatch-Waxman safe harbor.
- Erasca stated it believes the allegations are without merit and intends to contest them vigorously.
Financial Impact
High risk to future revenue potential of ERAS-0015; potential for significant legal costs, injunction, or royalty payments if litigation escalates.
Risk Factors
- ERAS-0015 development could be halted or delayed by litigation.
- Potential for material financial liability through damages or royalties if infringement is found.
- Reputational damage from trade secret allegations and comparative claims.
- Clinical data may be overshadowed by legal overhang, limiting positive market reaction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-179214 |
| Document: 0001193125-26-179214-index-headers.html | 0001193125-26-179214 |
| Document: 0001193125-26-179214-index.html | 0001193125-26-179214 |
| Document: 0001193125-26-179214.txt | 0001193125-26-179214 |
Track record
26 reports on ERAS
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
- Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
- Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
- Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
- Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers